SBTX - BELLUS Health Akoya Biosciences lead weakly healthcare gainers; Protagonist trail

Healthcare stocks in the S&P 500 edged past the ~0.6% loss in the broader index over the week to end ~0.2% lower, becoming the fourth best performing sector. Among stocks with more than $300M market cap and over 100K average daily volume over the past five sessions, BELLUS Health (NASDAQ:BLU) led the gainers in the sector with a ~53.8% rise thanks to positive interim findings from a mid-stage trial for the company’s chronic cough therapy BLU-5937. Seeking Alpha contributor Ari Zoldan, with a bullish rating on BELLUS (BLU), indicates a sizable market share for the treatment should it reach commercialization. Recently IPO’ed Akoya Biosciences (NASDAQ:AKYA) followed up with a gain of ~47.0%. In May, Marlborough, Massachusetts -based life sciences company, attracted bullish ratings from Wall Street as analysts initiated the coverage on the stock with price targets ranging from $25 – $28 per share. While Itamar Medical (NASDAQ:ITMR) jumped ~46.8% over the week following an agreement to be acquired

For further details see:

BELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trail